Pharmadrug CEO says completion of cGMP substance manufacturing advances its programs

PharmaDrug Inc (CSE:PHRX, OTCQB:LMLLF) CEO Daniel Cohen joined Proactive’s Stephen Gunnion with the news that the company has completed cGMP (good manufacturing practices) production of a multi-kilogram batch of cepharanthine-2HCl, a key ingredient in PD-001, the oral version of cepharanthine.

Cohen told Proactive that completion of this lot advances the company’s efforts to support pre-clinical and clinical development, including the commencement of Phase 2 clinical studies, for parallel indications in oncology and infectious disease.

#ProactiveInvestors #PharmaDrug #cGMP #cepharanthine #CSE #OTCQB

You might like

© 2022 The Latest StockMarket News and Interviews